Conversely, in cancer cells lines without the FLT3-ITD mutation (HeLa, MCF-7, and HT1080 cells), CRBN(FLT3)-8 exhibited minimal proliferation inhibition, even at micromolar concentrations, and was significantly less effective than gilteritinib. Here, FLT3 is linked to cancer.